Adragon, a global CDMO specialising in end to end production of small-molecule finished dosage forms, has invested €13 million ($13.67 million) in the expansion of a new filling line at its facility in Livron, France, marking a milestone in their project future.

The expansion will enhance production capacity by 30% with a focus on quality and compliance to support rising demand for sterile injectables. Production capacity will be increased to 160 million ampoules per year with flexible fill volumes (ranging from 1 to 20 ml). The addition of a new cleanroom is also intended to improve efficiency and innovation capabilities.